News & Events about Organovo Holdings Inc.
Lead Molecule Poised for Phase 2 in IBDSAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that ...
Organovo Holdings, Inc. (NASDAQ:ONVO Get Rating) saw a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 291,600 shares, a decline of 11.1% from the February 13th total of 327,900 shares. Based on an average daily volume of 111,700 ...
SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announced that it has successfully advanced the ...
Renaissance Technologies LLC trimmed its position in shares of Organovo Holdings, Inc. (NASDAQ:ONVO Get Rating) by 21.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120,887 shares of the ...